Pierre-Philippe Piché-Renaud

Pierre-Philippe Piché-Renaud

Auto-generated profile, based on publicly available information

Pierre-Philippe Piché-Renaud

Division of Infectious Diseases, The Hospital for Sick Children

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
PPPierre-Philippe Piché-Renaud
Pierre-Philippe Piché-Renaud
HGHelen E. Groves
Helen E. Groves
TKTaito Kitano
Taito Kitano
CACallum Arnold
Callum Arnold
ATAngela Thomas
Angela Thomas
MSMichelle Science
Michelle Science
Objective: In this study, we aimed to capture perspectives of healthcare workers (HCWs) on coronavirus disease 2019 (COVID-19) and infection prevention and control (IPAC) measures implemented during the early phase of the COVID-19 pandemic.Design: A cross-sectional survey of HCWs.Participants: HCWs from the Hospital for Sick Children, Toronto, Canada.Intervention: A self-administered survey was distributed to HCWs. We analyzed factors influencing HCW knowledge and self-reported use of personal protective equipment (PPE), concerns about contracting COVID-19 and acceptance of the recommended IPAC precautions for COVID-19.Results: In total, 175 HCWs completed the survey between March 6 and March 10: 35 staff physicians (20%), 24 residents or fellows (14%), 72 nurses (41%), 14 respiratory therapists (8%), 14 administration staff (8%), and 14 other employees (8%). Most of the respondents were from the emergency department (n = 58, 33%) and the intensive care unit (n = 58, 33%). Only 86 respondents (50%) identified the correct donning order; only 60 (35%) identified the correct doffing order; but the majority (n = 113, 70%) indicated the need to wash their hands immediately prior to removal of their mask and eye protection. Also, 91 (54%) respondents felt comfortable with recommendations for droplet and/or contact precautions for routine care of patients with COVID-19. HCW occupation and concerns about contracting COVID-19 outside work were associated with nonacceptance of the recommendations (P= .016 andP= .036 respectively).Conclusion: As part of their pandemic response plans, healthcare institutions should have ongoing training for HCWs that focus on appropriate PPE doffing and discussions around modes of transmission of COVID-19.

15 June 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
PPPierre-Philippe Piché-Renaud
Pierre-Philippe Piché-Renaud
ELErika Yue Lee
Erika Yue Lee
CJCatherine Ji
Catherine Ji
JHJenny Yu Qing Huang
Jenny Yu Qing Huang
EUElizabeth Uleryk
Elizabeth Uleryk
UAUpton D. Allen
Upton D. Allen
Synthesize the available evidence on the immunogenicity, safety, and effectiveness of live-attenuated varicella vaccine in solid organ transplant (SOT) recipients. Medline and EMBASE were searched using predefined search terms to identify relevant studies. Included articles reported varicella vaccine administration in the post-transplant period in children and adults. Pooled proportion of transplant recipients who seroconverted and who developed vaccine-strain varicella and varicella disease were generated. Eighteen articles (14 observational studies, 4 case reports) were included, reporting on 711 transplant recipients who received the varicella vaccine. The pooled proportion was 88.2% (95% confidence interval [CI] 78.0%-96.0%, 13 studies) for vaccinees who seroconverted, 0% (0%-1.2%, 13 studies) for vaccine-strain varicella and 0.8% (0%-4.9%, 9 studies) for varicella disease. Most studies followed clinical guidelines for administering live-attenuated vaccines with criteria that could include being at least one-year post-transplant, two months post-rejection episode, and on low-dose immunosuppressive medications. Varicella vaccination in transplant recipients was overall safe in included studies, with few cases of vaccine-strain induced varicella or vaccine failure, and while it was immunogenic, the proportion of recipients who seroconverted was lower than that seen in the general population. Our data support varicella vaccination in select pediatric solid organ transplant recipients.

8 September 2023 in Frontiers in Public Health
Verified
Journal Article
Open access
SWSusitha Wanigaratne
Susitha Wanigaratne
HLHong Lu
Hong Lu
SGSima Gandhi
Sima Gandhi
JSJanavi Shetty
Janavi Shetty
TSTherese A. Stukel
Therese A. Stukel
AGAstrid Guttmann
Astrid Guttmann
Introduction: Immigrants were disproportionately impacted by COVID-19 and experience unique vaccination barriers. In Canada (37 million people), 23% of the population is foreign-born. Immigrants constitute 60% of the country’s racialized (non-white) population and over half of immigrants reside in Ontario, the country’s most populous province. Ontario had several strategies aimed at improving vaccine equity including geographic targeting of vaccine supply and clinics, as well as numerous community-led efforts. Our objectives were to (1) compare primary series vaccine coverage after it was widely available, and first booster coverage 6 months after its availability, between immigrants and other Ontario residents and (2) identify subgroups experiencing low coverage.Materials and methods: Using linked immigration and health administrative data, we conducted a retrospective population-based cohort study including all community-dwelling adults in Ontario, Canada as of January 1, 2021. We compared primary series (two-dose) vaccine coverage by September 2021, and first booster (three-dose) coverage by March 2022 among immigrants and other Ontarians, and across sociodemographic and immigration characteristics. We used multivariable log-binomial regression to estimate adjusted risk ratios (aRR).Results: Of 11,844,221 adults, 22% were immigrants. By September 2021, 72.6% of immigrants received two doses (vs. 76.4%, other Ontarians) and by March 2022 46.1% received three doses (vs. 58.2%). Across characteristics, two-dose coverage was similar or slightly lower, while three-dose coverage was much lower, among immigrants compared to other Ontarians. Across neighborhood SARS-CoV-2 risk deciles, differences in two-dose coverage were smaller in higher risk deciles and larger in the lower risk deciles; with larger differences across all deciles for three-dose coverage. Compared to other Ontarians, immigrants from Central Africa had the lowest two-dose (aRR = 0.60 [95% CI 0.58–0.61]) and three-dose coverage (aRR = 0.36 [95% CI 0.34–0.37]) followed by Eastern Europeans and Caribbeans, while Southeast Asians were more likely to receive both doses. Compared to economic immigrants, resettled refugees and successful asylum-claimants had the lowest three-dose coverage (aRR = 0.68 [95% CI 0.68–0.68] and aRR = 0.78 [95% CI 0.77–0.78], respectively).Conclusion: Two dose coverage was more equitable than 3. Differences by immigrant region of birth were substantial. Community-engaged approaches should be re-invigorated to close gaps and promote the bivalent booster.

24 August 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PPPierre-Philippe Piché-Renaud
Pierre-Philippe Piché-Renaud
LPLuc Panetta
Luc Panetta
DFDaniel S. Farrar
Daniel S. Farrar
CMCharlotte Moore-Hepburn
Charlotte Moore-Hepburn
ODOlivier Drouin
Olivier Drouin
OTon behalf of the Canadian Paediatric Surveillance Program COVID-19 Study Team
on behalf of the Canadian Paediatric Surveillance Program COVID-19 Study Team
Background: There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical management and public health interventions. The objective of this study was to describe the clinical manifestations, disease severity, and characteristics associated with hospitalization among infants infected with the initial strains of SARS-CoV-2. Methods: This is a national, prospective study of infants with SARS-CoV-2 from April 8th 2020 to May 31st 2021 using the infrastructure of the Canadian Paediatric Surveillance Program. Infants <1 year of age with microbiologically confirmed SARS-CoV-2 infection from both inpatients and outpatients seen in clinics and emergency departments were included. Cases were classified as either: 1) Non-hospitalized patient with SARS-CoV-2 infection; 2) COVID-19-related hospitalization; or 3) non-COVID-19-related hospitalization (e.g., incidentally detected SARS-CoV-2). Case severity was defined as asymptomatic, outpatient care, mild (inpatient care), moderate or severe disease. Multivariable logistic regression was performed to identify characteristics associated with hospitalization. Results: A total of 531 cases were reported, including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. Among hospitalized infants, 141 of 199 infants (70.9%) were admitted because of COVID-19-related illness, and 58 (29.1%) were admitted for reasons other than acute COVID-19. Amongst all cases with SARS-CoV-2 infection, the most common presenting symptoms included fever (66.5%), coryza (47.1%), cough (37.3%) and decreased oral intake (25.0%). In our main analysis, infants with a comorbid condition had higher odds of hospitalization compared to infants with no comorbid conditions (aOR = 4.53, 2.06–9.97), and infants <1 month had higher odds of hospitalization then infants aged 1–3 months (aOR = 3.78, 1.97–7.26). In total, 20 infants (3.8%) met criteria for severe disease. Conclusions: We describe one of the largest cohorts of infants with SARS-CoV-2 infection. Overall, severe COVID-19 in this age group was found to be uncommon. Comorbid conditions and younger age were associated with COVID-19-related hospitalization amongst infants.

2 October 2020 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
PPPierre‐Philippe Piché‐Renaud
Pierre‐Philippe Piché‐Renaud
LTLouis‐Philippe Thibault
Louis‐Philippe Thibault
SESandrine Essouri
Sandrine Essouri
ACAnnik Chainey
Annik Chainey
CTCorinne Thériault
Corinne Thériault
NGNathalie Gaucher
Nathalie Gaucher

20 May 2024 in Vaccine
Verified
Journal Article
Open access
EKElahe Karimi-Shahrbabak
Elahe Karimi-Shahrbabak
Costanza Di ChiaraCostanza Di Chiara
Costanza Di Chiara
DFDaniel S. Farrar
Daniel S. Farrar
SFSarah M. Abu Fadaleh
Sarah M. Abu Fadaleh
JPJoelle Peresin
Joelle Peresin
SMShaun K. Morris
Shaun K. Morris
Although COVID-19 vaccine safety in 5-11-year-old children has been documented, half of Ontarian children this age remain unvaccinated. This study aimed to assess caregivers' vaccine acceptance for 5-11-year-old children and identify factors associated with vaccine non-acceptance. A multi-language self-administered survey was sent to caregivers of 5-11-year-old children through schools and community health centers within the Greater Toronto Area from April-July 2022. Sociodemographic characteristics and immunization behaviours were collected for caregivers, their 5-11-year-old children, and any older siblings. The primary outcome, COVID-19 vaccine acceptance, was previous uptake of COVID-19 vaccine or caregiver intent to vaccinate for their 5-11-year-old child. Data were analyzed using descriptive statistics and multivariable logistic regression. In total, 807 caregivers were included in analysis. Although 93 % of caregivers had received two doses of COVID-19 vaccine, 77 % had a 5-11-year-old child who received at least one dose of vaccine. Caregivers age was associated with vaccine acceptance (vs. < 40 years; adjusted odds ratio [aOR] 2.1, 95 % confidence interval [CI] 1.4-3.1 for ages 40-49; aOR 2.8, 95 % CI 1.1-7.1 for ages ≥50 years). Immunization factors associated with vaccine acceptance included caregiver COVID-19 vaccination (aOR 38.1 vs. unvaccinated caregivers; 95 % CI 15.8-92.3), older siblings COVID-19 vaccination (aOR 49.2 vs. unvaccinated siblings; 95 % CI 18.3-132.3), and recent influenza vaccination for the child (aOR 6.9 vs. no influenza vaccine; 95 % CI 4.6-10.5). Among 189 caregivers with unvaccinated 5-11-year-old children, the most common reasons for non-acceptance were concerns about long-term side effects (59 %), lack of experience vaccinating children (41 %), and concerns that vaccines were developed too quickly (39 %). Acceptance of COVID-19 vaccination for 5-11-year-old children were associated with caregiver vaccine behaviors and sociodemographic factors. These findings highlight groups of caregivers that can be targeted for educational interventions and concerns that may be addressed to increase vaccine confidence.